ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0929

UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin

Ahmed Eldaboush1, Cristina Ricco1, Luca Musante1, Rohan Dhiman2, Avital Baniel3, Daniella Faden1, Caroline Stone1, Ming-Lin Liu1 and Victoria Werth4, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Newport Coast, CA, 3Perelman School of Medicine, UPENN, Philadelphia, PA, 4University of Pennsylvania, Wynnewood, PA

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Mouse Models, Other, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Extracellular vesicles (EVs) are small lipid-bilayer particles released from cells that mediate various functions through their cargo, which includes proteins and nucleic acids. EVs have been linked to the pathogenesis of photosensitive autoimmune diseases such as dermatomyositis (DM) and systemic lupus erythematosus (SLE), and plasma-derived EVs from DM patients have been shown to induce type-1 interferon release. Ultraviolet-B (UVB) radiation can trigger flares of DM and SLE and cause significant skin and systemic inflammation. It is not well-understood how UVB can drive such effects when it is mostly absorbed by the epidermis, with only a small fraction reaching beyond the epidermis. We hypothesize that UVB provokes keratinocytes to release EVs that migrate into the dermis and play a role in dermal and systemic effects.

Methods: We irradiated the shaved dorsal skin of 3 male and 3 female C57BL/6 mice for 5 consecutive days with 150 mJ/cm² UVB and used 2 male and 2 female mice as controls. The skin was then harvested and scraped with a blade to remove the epidermis. The dermis was incubated for 30 minutes with a collagenase-dispase enzyme cocktail, and underwent differential ultracentrifugation at 100,000g for 2 hours, followed by iodixanol density-gradient ultracentrifugation at 100,000g for 16 hours and overnight membrane filtration to isolate dermal EVs. Hematoxylin & Eosin and immunohistochemical staining with anti-cytokeratin 1 verified the successful removal of the epidermis (Figure 1).

Results: Western blot (WB) and Exoview validated the purity of the EV prep by confirming the expression of tumor-susceptibility gene 101 (TSG101) and the tetraspanin surface marker CD81. Additionally, WB showed minimal expression of Calnexin, an endoplasmic reticulum protein, indicating that the EV prep was nearly free of cellular debris (Figure 2). Electron microscopy showed notable disruption of the basement membrane (BM) of the UVB-irradiated skin compared to the intact BM of sham-irradiated skin. Multiple round vesicle-like structures were visualized near both sides of the BM, more abundantly in the UVB-irradiated skin compared to sham-irradiated skin. Transmission Electron Microscopy of the enriched EV suspension revealed vesicular membrane structures with variable sizes ranging from 20 to 300 nanometers and EV-appropriate morphology.

Furthermore, WB, Exoview, and Immunogold electron microscopy (IEM) confirmed the expression of cytokeratin 10 (K10), a marker of keratinocyte differentiation, in the EVs isolated from the dermis, proving that these EVs are indeed epidermally derived from keratinocytes. Moreover, flow cytometry revealed that K10 was significantly more expressed in UVB-irradiated EVs than in sham-irradiated EVs (Figure 3).

Conclusion: These findings suggest that epidermally derived keratinocyte EVs can diffuse through the disrupted basement membrane and reach the dermis, potentially playing a role in the epidermal-dermal crosstalk in UVB-induced dermal and systemic effects seen in photodamage. Further work aims to investigate the immunostimulatory effects of these EVs on dermal and circulating immune cells.

The first and second authors contributed equally to this work.

Supporting image 1

Figure 1 . Hematoxylin & Eosin staining of intact and scraped UVB irradiated and sham-irradiated skin. Intact skin: A. sham-irradiated and B. UVB-irradiated; Scraped skin: C. sham-irradiated and D. UVB-irradiated. This shows a successful complete removal of the epidermis. magnification: 10,000x; scale bar=200 micrometer.

Supporting image 2

Figure 2. Western blot of isolated dermal EVs from UVB-irradiated murine skin exhibits higher expression of the common EV marker tumor susceptibility gene 101 (TSG101) compared to sham-irradiated EVs. UVB and sham-EVs show similar expression of the tetraspanin protein CD81. There is minimal presence of the negative EV marker/endoplasmic reticulum membrane protein Calnexin.

Supporting image 3

Figure 3. Flow cytometry of cytokeratin 10 (K10) expression in the extracellular vesicles isolated from the dermis showing higher expression of K10 in the UVB-irradiated EVs compared to the sham-irradiated EVs. * The asterisk denotes a statistical significance by one-tailed unpaired t-test, p-value = 0.0224


Disclosures: A. Eldaboush: None; C. Ricco: None; L. Musante: None; R. Dhiman: None; A. Baniel: None; D. Faden: None; C. Stone: None; M. Liu: None; V. Werth: AbbVie/Abbott, 2, Alpine immune sciences, 2, Amgen, 1, 5, anaptysbio, 2, AstraZeneca, 2, 5, Biogen, 2, 5, BMS, 2, 5, Cabaletta Bio, 2, Calyx, 2, Caribou, 2, Corbus, 5, CSL Behring, 2, 5, Cugene, 2, Evommune, 2, Gilead, 2, 5, GSK, 2, Horizon, 2, 5, Immunovant, 2, Innovaderm, 2, Janssen, 2, Lilly, 2, Merck, 2, Nuvig Pharmaceuticals, 2, Pfizer, 2, 5, Priovant, 5, Regeneron, 1, 5, Rome Pharmaceuticals, 2, 5, Sanofi, 2, Takeda, 2, UCB, 2, Ventus, 2, 5, Viela, 5, Xencor, 2.

To cite this abstract in AMA style:

Eldaboush A, Ricco C, Musante L, Dhiman R, Baniel A, Faden D, Stone C, Liu M, Werth V. UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/uvb-induced-keratinocyte-derived-extracellular-vesicles-cytokeratin-10-as-a-marker-of-epidermal-origin/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uvb-induced-keratinocyte-derived-extracellular-vesicles-cytokeratin-10-as-a-marker-of-epidermal-origin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology